Glucagon-like peptide-2 (GLP-2), a proglucagon-derived peptide, has been postulated to affect appetite at the level of the hypothalamus. To gain better insight into this process, a degradationresistant GLP-2 analog, human (Gly 2 )GLP-2(1-33) [h(Gly 2 )GLP-2] was intracerebroventricularly injected into mice to examine its action on food and water intake and also activation of hypothalamic anorexigenic ␣-melanocyte-stimulating hormone/proopiomelanocortin, neurotensin, and orexigenic neuropeptide Y, and ghrelin neurons. Central h(Gly 2 )GLP-2 administration significantly suppressed food and water intake with acute weight loss at 2 h. 
both regions known to be involved in the regulation of feeding behavior (12) . It has been speculated that GLP-2 also acts as a neurotransmitter and exerts similar actions like GLP-1 in the CNS (11, 13) .
The actions of GLP-1 and GLP-2 are mediated via unique G protein-coupled receptors. The GLP-1 receptor (GLP-1R) is widely expressed in the hypothalamus as compared with the restricted expression of the GLP-2 receptor (GLP-2R) in the hypothalamic ventromedial nucleus (VMH) and DMH (13) (14) (15) (16) (17) (18) . Thus, they may play distinct roles in appetite regulation despite being synthesized in the same neurons (12) . However, little is known of GLP-2-mediated signaling in appetite regulation. TangChristensen et al. (13) discovered that central administration of GLP-2 is involved in regulation of food intake in rats. Similarly, pharmacological doses of central long-acting GLP-2 inhibited short-term food intake in mice (15) . Therefore, the mechanisms of central GLP-2R action to induce reduction in food intake require further characterization.
The GLP-2R is predominantly expressed in the gastrointestinal tract and the CNS, with limited expression in lungs, cervix, vagal afferents, and other peripheral organs (19) . The signaling mechanisms of the GLP-2R activation are not completely understood due to the lack of cell models that endogenously express GLP-2R. Data collected from heterologous cell lines transfected with GLP-2R have demonstrated that cAMP-dependent pathways are activated by GLP-2 (17, 18) . Few studies have addressed central GLP-2R activation and the target hypothalamic neurons largely remain elusive. Thus, clonal, hypothalamic cell lines that endogenously express functional GLP-2R were used. We investigated activation of hypothalamic ␣-melanocyte-stimulating hormone (␣-MSH)/proopiomelanocortin (POMC), neurotensin, neuropeptide Y (NPY), and ghrelin neurons after GLP-2 exposure to determine signaling pathways involved.
Materials and Methods

Animals and cannula placement
Adult male C57BL/6 (8 -10 wk old, 25-30 g) mice were housed in individual polycarbonate cages in a temperature-controlled vivarium on a 12-h light, 12-h dark cycle. All animals were given ad libitum access to standard rodent chow and water at all times. Using flat-skull coordinates from bregma (anteroposterior, Ϫ0.825 mm; medio-lateral, 0 mm; dorso-ventral, Ϫ4.8 mm), a 26-gauge stainless steel guide cannula (Plastics One, Roanoke, VA) projecting into the third cerebral ventricle was implanted into each mouse. Correct cannula placement and the patency were verified 1 wk after surgery by intracerebroventricular (icv) injection of 250 ng of angiotensin II in 0.5 l of 0.9% saline. Angiotensin II induces a drinking a response, and only data from mice with positive drinking responses were included in subsequent analyses. After allowing the mice to recover for 7-14 d, they were handled daily for at least 1 wk before beginning the experiments. All procedures and manipulations were conducted in accordance with the protocols and guidelines approved by the University of Toronto Animal Care Committee.
Intracerebroventricular microinjections for the dose-response feeding study feeding study
The degradation-resistant human analog of GLP-2, h(Gly 2 )GLP-2, was obtained from American Peptide Co. (Sunnyvale, CA). For the animal treatment, h(Gly 2 )GLP-2 was dissolved in 0.9% saline on the day of treatment, and microinjections were administered 1 h before onset of the dark phase. To determine the dose of h(Gly 2 )GLP-2 to use in our neuronal activation by immunohistochemistry (IHC) study, we performed peptide dose-response feeding study using a range of doses of h(Gly 2 GLP-2 (100 ng, 1 g, and 5 g per mouse). Each mouse received either different doses of h(Gly 2 )GLP-2 or 0.9% saline in a total volume of 2 l by slow infusion over 15 min through the preimplanted cannula into the third ventricle using a 30-gauge injector attached by polyethylene tubing to a 2-l glass syringe (Hamilton, Reno, NV) (four mice per treatment group). Upon returning to their home cages, the mice were allowed to freely access premeasured amounts of chow and water. The effect of icv h(Gly 2 )GLP-2 on feeding was determined by measuring changes in food and water intake at 1 and 2 h after treatment.
Assessment of neuronal activation by c-Fos IHC
The effect of acute stimulation of central GLP-2R by h(Gly 2 )GLP-2 on the activation of hypothalamic neuropeptidergic neurons expressing either ␣-MSH, NPY, neurotensin, or ghrelin was studied in ad libitum-fed mice (four mice per treatment group). The mice were treated with either icv h(Gly 2 )GLP-2 or 0.9% saline as described above for the peptide dose-response feeding study. For the treatment, dose of 5 g of h(Gly 2 )GLP-2 was selected based on the initial dose-response feeding study. Two hours after treatment, mice were anesthetized, weighed, and perfused transcardially with ice-cold 0.1 M PBS followed by freshly prepared 4% paraformaldehyde solution. Brains were removed immediately, postfixed in 4% paraformaldehyde, serially cryoprotected in 15 and 30% sucrose solution, snap frozen in an isopentane bath, and stored at Ϫ80 C. For subsequent IHC analysis, frozen brains were cut with a cryostat (Leica CM1510S; Leica Microsystems, Concord, Canada) in a rostral to caudal direction in the coronal plane into 20-m sections, and serial sections were stored at Ϫ20 C in cryoprotectant.
The number of c-Fos-, ␣-MSH/POMC-, NPY-, neurotensin-, or ghrelin-immunoreactive neurons in specific hypothalamic regions was quantitatively assessed. The specific primary antibodies used for the detection of neuropeptide immunoreactivity were as follows: anti-c-Fos (1:25,000; Calbiochem, Mississauga, Ontario, Canada), antineurotensin (1:5000; ImmunoStar, Hudson, WI), antighrelin (1:1000; catalog no. H-031-31; Phoenix Pharmaceuticals, Burlingame, CA), anti-␣-MSH (1:200; catalog no. H-043-01; Phoenix Pharmaceuticals), and anti-NPY (1:1000; catalog no. H-049-03; Phoenix Pharmaceuticals). Biotinylated goat antirabbit IgG antibody was used as the secondary antibody. For the IHC, every alternate section at 20-m intervals through the hypothalamus was selected. Evenly spaced sections covering the region Ϫ0.70 to Ϫ1.94 mm from bregma were defined according to the mouse brain atlas of Paxinos and Franklin (20) . The conventional avidin-biotin-immunoperoxidase method using diaminobenzidine (DAB) as chromogen (Vectastain ABC Elite kit; Vector Laboratories, Burlington, Canada) was applied to detect c-Fos, ␣-MSH, NPY, neurotensin, or ghrelin immunoreactivity. IHC for nuclear c-Fos was performed with DAB to yield a brown nuclear reaction product, whereas IHC for cytoplasmic ␣-MSH/POMC, NPY, neurotensin, and ghrelin was performed using DAB with Metal Enhancer (cobalt chloride), yielding a more intense blue/black cytoplasmic reaction product (catalog no. D0426; Sigma, St. Louis, MO).
Immunostained brain sections were examined using a Zeiss Axioplan 2 microscope outfitted with an AxioCam HRc camera and AXIOVISION 4.2 imaging software (Zeiss, Oberkochen, Germany). For the quantification of immunostained cells, every alternate section throughout the arcuate nucleus (ARC), PVN, DMH, and VMH was taken to visualize the distribution of ␣-MSH/POMC, NPY, neurotensin, or ghrelin neurons throughout these nuclei (total three to four sections per mouse). For each of the ARC, PVN, DMH, VMH, lateral hypothalamic nucleus (LH), and internuclear spaces from either side, an image was captured in a single plane of focus at ϫ40 magnification, and a 100-m 2 box was placed in the center of the selected hypothalamic regions. c-Fos-immunoreactive cells contained brown nuclear staining, whereas ␣-MSH/POMC-, NPY-, neurotensin-, or ghrelin-immunoreactive cells contained dark blue/black cytoplasmic staining. Calculation of the immunoreactive cells was performed in a blindfold manner, and in each group, the mean value of the cell counts from three to four sections of an individual animal was used for statistical analysis. The results were expressed as the ratio of double-labeled cells coexpressing c-Fos with either ␣-MSH/POMC, NPY, neurotensin, or ghrelin to the total number of respective single-labeled neuropeptide-immunoreactive cells per 0.22-mm 2 area of the ARC, PVN, DMH, VMH, LH, or the internuclear regions.
Cell culture and reagents
Adult mouse hypothalamic mHypoA-2/30 neuronal cell line was used for the in vitro analysis. Generation of these cells from adult mouse hypothalamic primary neuronal cell culture has been previously described (21) . These cells were grown in DMEM (Sigma, Alberta, Canada), supplemented with 5% fetal bovine serum (HyClone Laboratories, Logan, UT) and 1% penicillin/streptomycin (Life Technologies, Inc., Burlington, Canada), and maintained at 37 C in an atmosphere of 5% CO 2 [44] . GLP-2(1-33) and h(Gly 2 )GLP-2 were purchased from American Peptide Co. Forskolin was obtained from Sigma-Aldrich (Oakville, Canada). 3-Isobutyl-1-methylxanthine and the protein kinase A (PKA) inhibitors H-89 and protein kinase inhibitor (PKI) (14) (15) (16) (17) (18) (19) (20) (21) (22) amide were purchased from Tocris Bioscience (Ellisville, MO).
Screening of mHypoA-2/30 cells for the expression of neuropeptides and receptors
To screen the cells for ghrelin, neurotensin, NPY, and GLP-2R genes OneStep RT-PCR was carried out using OneStep RT-PCR kit (QIAGEN, Toronto, Canada). The primer pairs used for the RT-PCR were designed using mouse sequences in GenBank to span introns, ruling out the possibility of genomic DNA contamination.
The specific primer sequences used were as follows: neurotensinsense (S), 5Ј-ataggaatgaaccttcagctg-3Ј and neurotensin-antisense (AS), 5Ј-gtaggaggccctcttgagtat-3Ј; ghrelin-S, 5Ј-agcatgctctggatggacatg-3Ј and ghrelin-AS, 5Ј-aggcctgtccgtggttacttgt-3Ј; NPY-S, 5Ј-taggtaacaagcgaatgggg-3Ј and NPY-AS, 5Ј-acatggaagggtcttcaagc-3Ј; histone-S, 5Ј-gcaagagtgcgccctctactg-3Ј and histone-AS, 5Ј-ggcctcacttgcctcgtgcaa-3Ј; and GLP-2R-S, 5Ј-tgctggtttccatcaagcaa-3Ј and GLP-2R-AS, 5Ј-atcagctgcaaggtggacaa-3Ј. OneStep RT-PCR was performed with 200 ng of total RNA template in a total volume of 25 l for all samples as described by the manufacturer (QIAGEN). All PCR-amplified products were visualized on 1.2% agarose gel containing ethidium bromide under UV light with the Kodak IS2000 digital imaging center (Eastman Kodak Co., Rochester, NY). The PCR amplicons were verified by purification and sequencing (The Centre for Applied Genomics, Toronto, Canada).
RIA for cAMP
GLP-2(1-33) was used to determine cAMP levels after GLP-2R activation in mHypoA-2/30 cells. The hypothalamic mHypoA-2/30 cells were split into 24-well plates until 80 -90% confluent and overnight incubated in serum-free DMEM. The cells were washed twice with PBS, pretreated for 5 min with 1 M GLP-2(3-33) or vehicle alone before a 10-min treatment with vehicle, forskolin (1 or 10 M), GLP-2 (10 or 50 nM), or h(Gly 2 )GLP-2 (10 nM), and incubated at 37 C. Forskolin was used as a positive control. All drugs were diluted in Opti-MEM containing 3-isobutyl-1-methylxanthine (100 mM). After incubation at 37 C, 1 ml of anhydrous ethanol at Ϫ20 C (final concentration, 77% ethanol) was added to the cells to terminate the reaction. The plates were allowed to sit at Ϫ20 C for 24 h. The extracts were collected, centrifuged, and the supernatant was analyzed for cAMP content by using cAMP-RIA kit (Biomedical Technologies, Inc., Stoughton, MA). cAMP levels were calculated relative to total amount of protein, as determined by the bicinchoninic acid protein assay kit (Thermo Scientific, Rockford, IL).
Quantitative RT-PCR (qRT-PCR) to investigate neuropeptide mRNA transcript regulation
In rest of the cell culture experiments, long-acting GLP-2, h(Gly 2 )GLP-2 was used. The EC 50 of GLP-2 and h(Gly 2 )GLP-2 for mouse GLP-2R is identical, and there is a high degree of similarity between their biological actions. Using guanidinium thiocyanate extraction method, total RNA was extracted from mHypoA-2/30 cells at the indicated time points over 24 h after treatment with vehicle or h(Gly 2 )GLP-2 (10 nM). Real-time qRT-PCR was performed with 2.0 g of total RNA using SYBR Green PCR Master Mix (Applied Biosystems, Inc., Burlington, Canada) and Applied Biosystems Prism 7000 real-time PCR machine. Sequences of the SYBR primers for the ␥-actin and ghrelin genes are as follows: ␥-actin-SYBR-S, 5Ј-cttccccacgccatcttg-3Ј and ␥-actin-SYBR-AS, 5Ј-cccgttcagtcaggatcttcat-3Ј; and ghrelin-SYBR-S, 5Ј-ggaggagctggagatcaggtt-3Ј and ghrelin-SYBR-AS, 5Ј-ggcccggccatgctgct-3Ј. TaqMan Gene Expression assay containing neurotensin-specific primers and probe (Applied Biosystems, Inc.) was used to determine neurotensin mRNA expression levels. Expression of the target genes was calculated relative to ␥-actin expression using standard curve method. The final changes in mRNA transcript expression were relative to the corresponding time-matched control.
SDS-PAGE and immunoblot analysis to investigate signaling mechanisms
Total protein from 80 -90% confluent mHypoA-2/30 cells was isolated as described previously (22) . Bicinchoninic acid protein assay kit (Thermo Scientific) was used to determine protein concentration. Total protein (20 g) was resolved on 8% SDS-PAGE gels, transferred onto Immun-Blot polyvinyl difluoride membrane (Bio-Rad, Hercules, CA), and immunoblotted using rabbit antisera directed toward phospho-cAMP response element-binding protein (CREB) (Ser133), total-CREB, and c-Fos (all at 1:500; all from Cell Signaling Technology, Beverly, MA). Primary antibody against G protein ␤-subunit (G␤) (1:1000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was used as an internal control. A horseradish peroxidise-conjugated antirabbit secondary antibody (1:5000; Cell Signaling Technology) was used. Immunoreactive bands were visualized using enhanced chemiluminescence (ECL Advance kit; GE Healthcare, Princeton, NJ). Protein was visualized on a Kodak Image Station 2000R, and the intensity of bands was quantified by densitometry analysis using Kodak 1D Image Analysis Software 3.6 (Eastman Kodak Co.).
Statistical analysis
All data are presented as mean Ϯ SEM. The results were analyzed using GraphPad Prism software (GraphPad Software, Inc., San Diego, CA). Statistical analysis was performed using one-or two-way ANOVA, and statistical significance was determined by post hoc analysis using Bonferroni test or Student's t test with P Ͻ 0.05.
Results
Effect of icv h(Gly 2 )GLP-2 on food and water intake and animal weight
To establish the efficacy of the h(Gly 2 )GLP-2, we assessed the result on food and water intake over a shortterm exposure. In the h(Gly 2 )GLP-2 dose-response study, cumulative food intake was significantly reduced by 66.67% by icv dose of 5 g of h(Gly 2 )GLP-2, as compared with saline at 1 h after treatment in ad libitum-fed wildtype mice (Fig. 1A) . At 2 h after treatment, no additional food intake suppression was detected. On the contrary, the suppression of cumulative food intake was attenuated, and it did not differ across all treatment groups (Fig. 1A) . We found that different doses of h(Gly 2 )GLP-2 did not have any significant effect on cumulative water intake at 1 h after treatment (Fig. 1B) . In contrast, at 2 h after treatment, cumulative water intake was significantly reduced by 41.75 and 43.75% by both icv doses of 1 and 5 g of h(Gly 2 )GLP-2, respectively, as compared with saline treatment (Fig. 1B) . Based on the dose-response curves for anorexia induced by h(Gly 2 )GLP-2, we sought to determine its effect on body weight for which we selected the dose of 5 g of h(Gly (Fig. 1C) . We did not investigate further duration of these rapid weight losses.
Effect of h(Gly 2 )GLP-2 on activation of hypothalamic nuclei and neuropeptidergic neurons
As assessed by IHC for c-Fos expression, we noted a distinctive pattern of neuronal activation after the central injection of h(Gly 2 )GLP-2 compared with the saline controls (Fig. 2, A-F GLP-2 inhibits food and water intake and induces weight loss in a dose-dependent manner in wild-type mice. To determine the efficacy of icv h(Gly 2 )GLP-2 to induce anorexia, ad libitum-fed mice received injection of either 100 ng, 1 g, or 5 g of h(Gly 2 )GLP-2 dissolved in 2 l of 0.9% normal saline 1 h before the onset of the dark cycle. Mice were returned to their home cages with preweighed amount of chow and water. Changes in food (A) and water (B) intake, and animal weight (C), were measured at 1 and 2 h after injection; 0.9% normal saline solution was used as control treatment. All results are expressed as mean Ϯ SEM (n ϭ 3-4 mice/group); *, P Ͻ 0.05 vs. saline.
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Dalvi and Belsham GLP-2R Agonist Action in Hypothalamic Neurons Endocrinology, May 2012, 153(5):2385-2397 ARC (increase by 152%), DMH (increase by 342%), VMH (increase by 99%), LH (increase by 411%), and PVN (increase by 429%) (Fig. 2G ). Our next goal was to determine the neuropeptidergic neurons activated in the hypothalamic nuclei by performing double-staining IHC for c-Fos and neuropeptide coexpression (Figs. 3 and 4) . We found that in the ARC, single dose of icv h(Gly 2 )GLP-2 significantly increased the number of c-Fos-expressing ␣-MSH/POMC neurons by 105% (Fig. 5B) , NPY neurons by 140% (Fig. 5D ), neurotensin neurons by 332% (Fig. 5F ), and ghrelin neurons by 87% (Fig. 5H) . Further, we found that in the hypothalamic PVN, h(Gly 2 )GLP-2 robustly increased the number of c-Fos-positive nuclei with neurotensin coexpression by 504% (Fig. 5F ) and ghrelin coexpression by 233% (Fig.  5H ). In the hypothalamic DMH, we detected a significant increase in c-Fos and neurotensin and NPY coexpressing neorons by 416 and 334%, respectively, (Fig. 5H) . The number of c-Fos-positive nuclei coexpressing neurotensinimmunoreactivity was significantly increased by 404% in the VMH and by 535% in the LH. Also, the number of c-Fos-positive nuclei coexpressing ghrelin-immunoreactivity was significantly increased by 242% in the internuclear space between DMH and LH. The number of neurons expressing only neuropeptide-immunoreactivity remained unchanged in these hypothalamic regions of saline-or h(Gly 2 )GLP-2-treated animals (Fig. 5, A, C, E, and G) .
Expression of GLP-2R and appetite-regulating neuropeptides in adult mHypoA-2/30
To investigate direct regulation of hypothalamic neurotensin and ghrelin mRNA expression by h(Gly 2 )GLP-2, we used clonal, immortalized hypothalamic neuronal cell model, adult mHypoA-2/30 neuronal cell line. Before using this cell model, we confirmed the presence of GLP-2R mRNA in the mHypoA-2/30 neuronal cells using RT-PCR (Fig. 6A) . In another cell model, embryonic mHypoE-36/1 cell line, GLP-2R gene expression was not confirmed. GLP-2R-positive mouse jejunal tissue mRNA was used as a positive control. We also analyzed the expression of hy- 
pothalamic neuropeptides involved in appetite regulation in these cell lines and found that neurotensin and ghrelin genes are expressed in this cell line (Fig. 6B) . Currently, there are no hypothalamic cell models reported with a functional endogenous GLP-2R. Therefore, we sought to determine whether the GLP-2R is active in the adult mHypoA-2/30 neuronal cells by cAMP-RIA after GLP-2 treatment using two different concentrations (10 and 50 nM). Forskolin (1 M) was used as a positive control for cAMP activation. By cAMP-RIA, we found that both doses of GLP-2 significantly increased cAMP levels in the neuronal cell line (Fig. 6C) . Increases in the cAMP content indicate that GLP-2R expressed in these cells is functional and responsive to GLP-2. Further, using GLP-2(3-33), a GLP-2R antagonist, we studied whether h(Gly 2 )GLP-2 directly activates GLP-2R to stimulate cAMP production. We found that 1 M GLP-2(3-33) alone did not stimulate cAMP production but completely attenuated the stimulatory effect of h(Gly 2 )GLP-2, suggesting that h(Gly 2 )GLP-2 stimulates cAMP production via GLP-2R activation (Fig. 6D) .
Activation of CREB/activating transcription factor-1 (ATF-1) and c-Fos by h(Gly 2 )GLP-2 in the hypothalamic neuronal cells
The key signaling pathway that GLP-2 activates is the cAMP/PKA pathway. We next determined whether this classic GLP-2R signaling pathway is activated by h(Gly 2 )GLP-2 in our hypothalamic adult neuronal cells.
The neuronal cells were treated with 10 nM h(Gly 2 )GLP-2, and activation of CREB/ATF-1 and c-Fos was analyzed over 6 h. By Western blot analysis, we found that h(Gly 2 )GLP-2 significantly induced c-Fos activation by 62% in the adult mHypoA-2/30 cell line at 2 h (Fig. 7A) . Similarly, h(Gly 2 )GLP-2 significantly increased phosphorylation of CREB at Ser133 at 15 min, 1 h, and 2 h by 63, 33, and 59%, respectively, in the adult neuronal cells (Fig. 7B) . Simultaneously, h(Gly 2 )GLP-2 induced significant increase in phosphorylation of ATF-1 from 5 min to 6 h, and the maximum increase was by 72% at 2 h after treatment in these neuronal cells (Fig. 7C) . Regulation of neurotensin and ghrelin mRNA transcript expression by h(Gly 2 )GLP-2 Next, we determined whether h(Gly 2 )GLP-2 regulated mRNA transcript levels of neurotensin and ghrelin. The adult hypothalamic neuronal cells were exposed to 10 nM h(Gly 2 )GLP-2 over a 24-h time course. Using real-time qRT-PCR, we found that in the adult mHypoA-2/30 neurons, neurotensin mRNA levels were significantly up-regulated by 50% at 24 h after treatment (Fig. 8A) . Similarly, we found that h(Gly 2 )GLP-2 caused significant increase in mRNA levels of ghrelin by 95% at 24 h after treatment in the adult mHypoA-2/30 cell line (Fig. 8B) . These results clearly indicate that neurotensin and ghrelin genes are regulated by GLP-2R activation in the hypothalamic neuronal models and complement our findings within the in vivo setting.
A ARC (α-MSH-ir)
FIG. 3. Acute h(Gly 2 )GLP-2 treatment induces c-Fos-immunoreactivity (ir) in the hypothalamic neurons expressing ␣-MSH-, NPY-, neurotensin (NT)-, or ghrelin (Ghr)-ir. A-L, Bright-field photomicrographs showing neurons that coexpress c-Fos-ir (brown nuclei) and neuropeptide-ir (blue-
PKA inhibitors reverse the h(Gly 2 )GLP-2-induced up-regulation of neurotensin and ghrelin mRNA transcript levels
We then investigated role of PKA, a cAMP-dependent protein kinase, in the regulation of neurotensin and ghrelin )GLP-2 treatment significantly induced increase in the neurotensin mRNA levels (Fig. 8C) . Further, we found that both PKA inhibitors did not affect the basal neurotensin mRNA levels but significantly attenuated the h(Gly 2 )GLP-2-induced increase in neurotensin mRNA levels in the mHypoA-2/30 neuronal cell model (Fig. 8C) . Next, we investigated role of PKA in the ghrelin mRNA up-regulation caused by h(Gly 2 )GLP-2. At 24 h, h(Gly 2 )GLP-2 significantly increased ghrelin mRNA levels compared with the vehicle treatment (Fig. 8D) . Similar to the suppression of neurotensin mRNA levels, we detected that at 24 h, both PKA inhibitors attenuated the h(Gly 2-induced up-regulation in ghrelin mRNA levels (Fig. 8D) . Overall, these results indicate that PKA activation is involved with the regulation of neurotensin and ghrelin mRNA by h(Gly 2 )GLP-2.
Discussion
The proglucagon system plays an important role in the central regulation of energy homeostasis (11, 23 ). Many studies have described the hypothalamic actions of GLP-1 on energy homeostasis. However, the potential effects of GLP-2 still remain largely unknown. The hypothalamus is comprised of various nuclei, a subdivision of which are known to be involved in the regulation of feeding behavior. Besides the well-documented NPY and POMC neurons, two other major regulators of energy homeostasis, neurotensin and ghrelin neurons are also expressed within the ARC (24 -27) . The neurotensin system in the hypothalamus is extensive, and strong neurotensin immunoreactivity is found in the ARC, PVN, DMH, and LH, with low immunoreactivity in the VMH (26, 28) . Ghrelin neurons are also located in the PVN, the perifornical region, and the internuclear spaces between hypothalamic nuclei (24) . At present, the neuronal phenotypes expressing GLP-2R in the DMH and VMH are not clear. GLP-2 activates hypothalamic neuropeptidergic neurons. Note that there was no change in the number of neurons expressing only ␣-MSH-ir (A), NPY-ir (C), neurotensin-ir (E), or ghrelin-ir (G) in the hypothalamic regions of saline-or h(Gly 2 )GLP-2-treated animals. Data are represented as mean Ϯ SEM (n ϭ 3-4 mice/group); *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001 vs. saline treatment. Statistical significance was calculated by two-tailed, unpaired t test.
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entially activated ␣-MSH/POMC, NPY, neurotensin, and ghrelin neurons in a number of these regions. Our findings indicate that GLP-2R activation involves complex interactions between several hypothalamic nuclei, acute activation of feeding-related neuropeptidergic neurons, and longer-term transcriptional regulation of downstream neuropeptides. Central h(Gly 2 )GLP-2 administration activated several hypothalamic regions with a distinct pattern of c-Fos expression in comparison with the long-acting GLP-1R agonist, exendin-4 (47). Not only the major nuclei that lie in the vicinity of the third ventricle were activated but also the lateral hypothalamus was activated. Because the DMH and VMH have been demonstrated to express GLP-2R, activation of c-Fos in these areas suggests direct action of the h(Gly 2 )GLP-2. However, activation of ARC, PVN, and LH could be due to indirect activation, because GLP-2R expression is not found in these regions (13, 15) . Because these regions function together to regulate energy balance (29) , their indirect activation by GLP-2R-expressing neurons is quite possible. Interestingly, except for the VMH, these hypothalamic regions highly express GLP-1R (14) . Thus, there is a remote possibility of cross-reactivity of h(Gly 2 )GLP-2 with GLP-1R at the pharmacological dose used in the present study. However, it has been demonstrated that h(Gly 2 )GLP-2 activates only the cells with GLP-2R expression but not those expressing GLP-1R (15) . Moreover, the effects of h(Gly 2 )GLP-2 on food intake in GLP-1R knockout mice were not attenuated by disruption of GLP-1R signaling but rather potentiated, suggesting that GLP-2 does not mediate its effects on feeding through GLP-1R (15) . However, based on the activation of several hypothalamic nuclei by pharmacological h(Gly 2 )GLP-2 found by us, specificity of GLP-2, action in the hypothalamus needs to be investigated further using GLP-2R antagonists or GLP-2R knockdown strategy.
The detection of significant activation of NPY and neurotensin neurons in the DMH and neurotensin neurons in the VMH coordinates well with the expression of GLP-2R in these areas. However, whether NPY or neurotensin neurons express GLP-2R in vivo is not known. The significant increase in the number c-Fos-immunoreactive ␣-MSH/POMC, NPY, neurotensin, and ghrelin neurons in those areas that do not express GLP-2R is intriguing. tivation of all these areas by h(Gly 2 )GLP-2 implies a complex interaction between these nuclei and neurons that ultimately enhances the perception of satiety and thereby facilitates anorexia and decreased body weight.
Apart from appetite regulation, other potential actions from the pharmacological activation of central GLP-2R have yet to be fully delineated. GLP-2 has been shown to reduce glutamate-induced cell death in cultured murine hippocampal and cortical cells (30) . Similarly, ghrelin is also found to exert neuroprotective effects by its antiinflammatory action in the CNS (31) . Thus, ghrelin may potentially mediate antiinflammatory action and thereby neuroprotective effects of central GLP-2R action (30) . Further, GLP-2 has been shown to stimulate proliferation of cultured rat astrocytes (32) . A synthetic neurotensin agonist was found to induce an increase in the proliferation of the astrocytic cell lines (33) , whereas ghrelin was demonstrated to promote neurogenesis (34, 35) . Whether neurotensin and ghrelin act as downstream effectors of GLP-2 action in cell proliferation is not known and requires further study. Furthermore, GLP-2-mediated regulation of murine hippocampal neurons by increasing glucose uptake implicates an important role for GLP-2 in neurotransmitter release and hormone secretion from GLP-2R-positive neurons and endocrine cells (36) . Because hypothalamic ␣-MSH/POMC, NPY, and ghrelin neurons are implicated in glucose regulation (27, 37, 38) , whether GLP-2-mediated activation plays any role in peripheral glucose metabolism needs to be explored further. Our study focused exclusively on the action of GLP-2 in the hypothalamus, but extrahypothalamic action of GLP-2 also needs to be investigated.
The direct action of GLP-2 on the regulation of hypothalamic neuropeptides remains unstudied due to the lack of endogenous GLP-2R-expressing neuronal cells. Thus, we used the adult-derived hypothalamic mHypoA-2/30 neuronal cell model that expresses functional GLP-2R. The hypothalamic cell model represents a clonal, homogeneous population of a single neuron and provides a useful tool to perform gene regulation and mechanistic studies that are quite challenging to perform in vivo (21) . GLP-2 stimulates cAMP production and activates PKA to exert its CNS actions (30, 36, 39) . Therefore, we focused on the cAMP/PKA pathway in the regulation of hypotha- lamic neurotensin and ghrelin mRNA expression. Direct GLP-2R activation lead to an increase in intracellular cAMP and activation of transcription factors CREB and ATF-1. Furthermore, we observed an increase in c-Fos expression in these neuronal cells that correlates well with the in vivo c-Fos activation found in the GLP-2R-expressing DMH and VMH neurons, suggesting that these neurons could be directly activated by central h(Gly 2 )GLP-2. Similarly, GLP-2 was found to increase c-Fos mRNA in BHK-GLP-2R cells as well as in astrocytes to promote cellular proliferation (18, 32) , again pointing to the involvement of Glp-2 in cell proliferation.
Neurotensin and its receptor [neurotensin receptor (Ntsr)] are widely expressed in the CNS controlling a number of physiological functions, such as regulation of circadian rhythm, antipsychotic action, analgesia, thermoregulation, regulation of hypothalamic-pituitary-adrenal axis, and neuromodulation of dopamine neurotransmission. Particularly, hypothalamic neurotensin neurons are known to regulate feeding behavior (40) . Ntsr deficiency moderately increases food intake and body weight, and blocks neurotensin-induced anorexia in mice, implicating neurotensin-Ntsr signaling pathway in feeding and body weight regulation (41) . The observed increase in neurotensin transcript levels in the present study suggests that GLP-2 may activate neurotensin in favor of anorexigenic action quite similar to other satiety-inducing neuropeptides and hormones.
Central ghrelin-expressing neurons in the hypothalamus are the main source of ghrelin in the CNS (24, 42) . Apart from the peripheral ghrelin, it is reported that central ghrelin is also involved in the regulation of food intake and body weight (43, 44) . In our hypothalamic neuronal cell model, we observed a stimulatory effect on ghrelin mRNA expression. Recently, we found that GLP-1R activation by exendin-4 induced a decrease in the ghrelin mRNA levels in agreement with the anorexigenic action of GLP-1R agonism (Dalvi, P. S., and D. D. Belsham, unpublished data). Also, insulin, a satiety factor and adiposity signal, was shown to directly inhibit ghrelin expression in another hypothalamic cell model (45) . Similar to the exendin-4 or insulin, we were expecting negative regulation of ghrelin mRNA expression due to its orexigenic characteristics. The positive regulation may suggest that ghrelin could play a role in the promotion of hypothalamic neuronal survival, because ghrelin is known to exert an- tiinflammatory and neuroprotective effects in rat brain (31) . Although, ghrelin and neurotensin exert opposite effects on food intake and energy homeostasis, they exert comparable actions in improving memory and learning, as is evident from decreased ghrelin and neurotensin mRNA transcript expression in the brains of patients suffering from Alzheimer's disease (46) . Thus, it is possible that GLP-2-activated hypothalamic ghrelin and also neurotensin neurons may potentially exert other functions unrelated to appetite regulation In summary, the results of the present study demonstrate that pharmacological action of central GLP-2 results in activation of multiple hypothalamic regions to trigger complex interactions between appetite-regulating neuropeptidergic neurons to induce transient anorexigenic effect. Using a novel GLP-2R-positive hypothalamic cell line, we found that h(Gly 2 )GLP-2, in a PKA-dependent manner, directly regulates gene transcript expression of feeding-related neuropeptides neurotensin and ghrelin. Overall, these findings suggest that central GLP-2R may serve as a potential target for pharmacological intervention to modulate neuropeptides involved in appetite regulation.
